Plastic biocompatibility testing is the scientific evaluation of polymeric materials to ensure they do not produce harmful biological responses when they contact living tissue, blood, or mucosal surfaces in medical and healthcare applications. Performed in accordance with the ISO 10993 series of standards, this testing is a mandatory regulatory requirement for medical device manufacturers worldwide. This guide explains the testing samples, test items, methodologies, and application scenarios involved in evaluating the biological safety of plastic materials.
Technical Overview
Biocompatibility testing for plastics assesses whether polymeric materials used in medical devices, pharmaceutical packaging, and healthcare products can interact safely with the human body without causing cytotoxic, irritant, sensitizing, genotoxic, or thrombogenic effects. Because plastics contain additives such as plasticizers, stabilizers, colorants, antioxidants, residual monomers, and processing aids, there is inherent risk that these substances may migrate out of the material during patient contact and trigger adverse biological reactions.
The internationally recognized framework for biological evaluation is the ISO 10993 series of standards, which establishes a risk-based approach to determining the appropriate scope of testing. Regulatory authorities in major markets, including the United States FDA, the European Union under the EU MDR, and China under NMPA requirements, expect manufacturers to demonstrate biological safety through a documented evaluation process supported by test data from accredited third-party laboratories. In China, the equivalent national standard series is GB/T 16886, which is harmonized with ISO 10993.
Modern biological evaluation increasingly emphasizes chemical characterization of materials, extractables and leachables analysis, and toxicological risk assessment, allowing manufacturers to reduce animal testing through analytical justification. Nevertheless, core endpoint tests such as cytotoxicity, sensitization, and irritation remain the foundation of most biocompatibility test batteries for plastic materials.
Testing Samples
Raw Polymer Resins and Pellets
Material suppliers frequently submit base polymers in pellet or powder form for screening-level biological evaluation. Testing resin lots helps establish a material master file that device manufacturers can reference, and supports supplier qualification programs for medical-grade plastics.
Finished Medical Devices and Components
Complete devices or patient-contact components, such as tubing sets, catheter shafts, syringe barrels, luer connectors, housings, and infusion chambers, are tested in their final processed form. This is important because molding, extrusion, assembly, sterilization (ethylene oxide, gamma, or e-beam), and printing can all alter the biological profile of a plastic.
Molded, Extruded, and Cured Test Coupons
When finished devices are unavailable or impractical to test, representative coupons processed under production-equivalent conditions are prepared. These specimens preserve the thermal history, surface finish, and post-processing treatments of the actual product.
Material Extracts
Most in vitro and in vivo tests are performed on aqueous and non-aqueous extracts prepared according to ISO 10993-12. Polar media typically include sodium chloride injection or water, while non-polar media include vegetable oils such as cottonseed oil or sesame seed oil.
Common Plastic Materials Requiring Evaluation
- Polyvinyl chloride (PVC), flexible and rigid grades
- Polyethylene (PE) and ultra-high molecular weight polyethylene (UHMWPE)
- Polypropylene (PP) and random or impact copolymers
- Polystyrene (PS), ABS, and styrene-based copolymers
- Polycarbonate (PC) and polymethyl methacrylate (PMMA)
- Polyurethane (PU) and thermoplastic polyurethane (TPU)
- Silicone elastomers and thermoplastic elastomers (TPE)
- Fluoropolymers such as PTFE and FEP
- Engineering polymers such as PEEK, PET, and polyamide (nylon)
Testing Items
The selection of test endpoints depends on the nature and duration of body contact, as defined in ISO 10993-1. Typical test items for plastic materials include:
- In vitro cytotoxicity
- Skin sensitization (delayed-type hypersensitivity)
- Skin, mucosal, and intracutaneous irritation
- Acute systemic toxicity
- Pyrogenicity, including bacterial endotoxins
- Hemocompatibility, covering hemolysis, thrombogenicity, complement activation, and coagulation
- Genotoxicity, including bacterial reverse mutation (Ames), chromosomal aberration, and mouse micronucleus assays
- Subacute and subchronic systemic toxicity
- Local effects after implantation
- Chronic toxicity and carcinogenicity, when warranted by risk assessment
- Material-mediated pyrogenicity and reproductive or developmental toxicity for long-term contact devices
Testing Methods
Sample Preparation and Extraction
ISO 10993-12 governs the preparation of test samples and reference materials. Extraction ratios are based on surface area for formed articles (commonly 3 cm² per mL for thicknesses of 0.5 to 1 mm) or on mass for irregular or absorbent materials (commonly 0.2 g per mL or 0.1 g per mL). Standard extraction conditions include 37°C for 72 hours, 50°C for 72 hours, 70°C for 24 hours, and 121°C for 1 hour, selected to simulate or exaggerate clinical use without degrading the polymer.
In Vitro Cytotoxicity Testing
ISO 10993-5 defines three principal test options: the extract (elution) method, the direct contact method, and the indirect contact method using agar diffusion or filter diffusion. In the widely used extract method with MTT or neutral red uptake, L929 mouse fibroblast cells are exposed to material extracts and viability is quantified; a reduction in viability greater than 30 percent relative to controls classifies the sample as cytotoxic.
Sensitization Testing
ISO 10993-10 specifies procedures such as the guinea pig maximization test (GPMT), the closed-patch (Buehler) test, and the murine local lymph node assay (LLNA). In vitro alternatives are gaining acceptance where validated. These studies detect whether leachable substances from the plastic can induce delayed contact hypersensitivity.
Irritation Testing
ISO 10993-23, which superseded the irritation provisions of ISO 10993-10, describes intracutaneous reactivity testing in rabbits, in which extracts are injected intradermally and scored for erythema and edema. Validated in vitro reconstructed human epidermis (RhE) methods are increasingly accepted for skin irritation screening.
Acute and Subchronic Systemic Toxicity
Under ISO 10993-11, extracts are administered to mice or rats by oral, dermal, intravenous, or intraperitoneal routes, and animals are observed for clinical signs, body weight change, and mortality. Subacute studies extend dosing over 14 to 28 days with histopathological examination where required.
Hemocompatibility Testing
ISO 10993-4 addresses devices with direct or indirect blood contact. The hemolysis test measures the percentage of red blood cell lysis upon exposure to material extracts or direct contact, with results typically compared against accepted thresholds such as less than 5 percent hemolysis. Complement activation (C3a, SC5b-9), thrombogenicity, and coagulation assays may be added for blood-circulating devices such as oxygenators and dialyzers.
Genotoxicity Testing
ISO 10993-3 requires a battery approach, commonly combining the bacterial reverse mutation test with an in vitro chromosomal aberration assay or mouse lymphoma assay, and an in vivo micronucleus test where indicated. A positive finding triggers chemical characterization and leachables identification to determine the causative substance.
Chemical Characterization and Toxicological Risk Assessment
ISO 10993-18 and ISO 10993-17 support analytical biocompatibility, in which extractables and leachables are identified and quantified using GC-MS, LC-MS, and ICP-MS, and each detected compound is evaluated against health-based exposure limits. This approach is now a central element of biological evaluation files submitted to regulators.
Applications
Plastic biocompatibility testing supports regulatory submissions and safe commercialization across a broad range of healthcare sectors:
- Infusion therapy and anesthesiology products: IV catheters, infusion sets, syringes, stopcocks, and extension tubing made of PVC, PP, and PC
- Blood contact and extracorporeal devices: blood bags, dialyzers, blood oxygenators, and apheresis kits
- Long-term implants: PEEK spinal cages, UHMWPE bearing surfaces, PMMA bone cement, and silicone implants
- Respiratory and anesthesia equipment: masks, breathing circuits, humidifier chambers, and endotracheal tubes
- Pharmaceutical primary packaging: prefillable syringes, vials, closures, and IV bags evaluated for material safety
- In vitro diagnostic consumables: pipette tips, microplates, sample cups, and reagent bottles for laboratory use claims
- Dental materials: denture bases, aligners, provisional crowns, and orthodontic appliances
- Wearable and consumer health devices: smartwatch housings, sensor patches, and fitness trackers with prolonged skin contact
- Cosmetics and personal care packaging requiring biological safety justification for skin contact claims
FAQ
Which biocompatibility tests are mandatory for a new plastic medical device? There is no universal fixed set. ISO 10993-1 requires a risk-based endpoint matrix determined by body contact type (surface, external communicating, or implant) and contact duration (limited, prolonged, or long-term). For most limited-contact surface devices, cytotoxicity, sensitization, and irritation constitute the core battery.
How long does plastic biocompatibility testing take? Cytotoxicity testing typically requires one to two weeks. Sensitization studies require approximately four to eight weeks depending on the method, irritation studies about three weeks, and acute systemic toxicity about two weeks. Genotoxicity batteries and implantation studies can extend over several months, so manufacturers should plan testing early in development.
Is GB/T 16886 the same as ISO 10993? GB/T 16886 is the Chinese national standard series corresponding to ISO 10993 and is technically aligned in most parts. Data generated under one system is generally acceptable under the other, although NMPA submissions may require testing in laboratories meeting specific accreditation requirements.
Do I need to retest when I change my plastic supplier or resin grade? Any change in resin formulation, supplier, processing conditions, or sterilization method can affect biological safety and requires a documented change impact evaluation. Retesting or a chemical characterization comparison may be necessary to justify continued use of existing data.
What is the difference between USP Class VI and ISO 10993 testing? USP Class VI is a plastics classification scheme based on a defined set of animal tests, while ISO 10993 defines a comprehensive, risk-based biological evaluation framework. Most global regulators now expect ISO 10993-based evaluations, although USP Class VI certification remains a common supplier specification for medical-grade polymers.
Can chemical characterization replace biological testing? Not entirely. Analytical data under ISO 10993-18 combined with toxicological risk assessment under ISO 10993-17 can justify waiving certain animal tests, but in vitro cytotoxicity and, in most cases, sensitization and irritation data are still expected as part of the overall biological safety evaluation.